

# Alain Stăpanian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3804441/publications.pdf>

Version: 2024-02-01

49  
papers

2,254  
citations

331670

21  
h-index

223800

46  
g-index

55  
all docs

55  
docs citations

55  
times ranked

3736  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	11.9	357
2	Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. <i>Lancet Haematology</i> , 2016, 3, e237-e245.	4.6	218
3	Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. <i>Blood</i> , 2012, 119, 5888-5897.	1.4	206
4	Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. <i>Haematologica</i> , 2017, 102, 1494-1501.	3.5	164
5	Cardiovascular and Thromboembolic Risk Factors in Idiopathic Sudden Sensorineural Hearing Loss: A Case-Control Study. <i>Audiology and Neuro-Otology</i> , 2011, 16, 55-66.	1.3	134
6	Microparticle increase in severe obesity: Not related to metabolic syndrome and unchanged after massive weight loss. <i>Obesity</i> , 2013, 21, 2236-2243.	3.0	114
7	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	7.1	110
8	High Prevalence of Deep Vein Thrombosis in Mechanically Ventilated COVID-19 Patients. <i>Journal of the American College of Cardiology</i> , 2020, 76, 480-482.	2.8	82
9	Von Willebrand Factor and ADAMTS13. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1703-1709.	2.4	72
10	Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?. <i>Thrombosis Research</i> , 2020, 195, 74-76.	1.7	64
11	Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis. <i>Medicine (United States)</i> , 2015, 94, e1692.	1.0	62
12	Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. <i>Lancet Haematology</i> , 2016, 3, e537-e546.	4.6	53
13	Reference values for rotation thromboelastometry (ROTEM®) parameters following non-haemorrhagic deliveries. Correlations with standard haemostasis parameters. <i>Thrombosis and Haemostasis</i> , 2011, 106, 176-178.	3.4	46
14	Apelin: an antithrombotic factor that inhibits platelet function. <i>Blood</i> , 2016, 127, 908-920.	1.4	45
15	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1740.	2.4	43
16	ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1902-1917.	3.4	40
17	Highly Significant Association between Two Common Single Nucleotide Polymorphisms in CORIN Gene and Preeclampsia in Caucasian Women. <i>PLoS ONE</i> , 2014, 9, e113176.	2.5	31
18	Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. <i>Thrombosis Research</i> , 2019, 184, 86-91.	1.7	30

#	ARTICLE	IF	CITATIONS
19	Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. <i>Thrombosis Research</i> , 2014, 134, 1074-1080.	1.7	28
20	von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate to severe COVID-19 patients. <i>British Journal of Haematology</i> , 2021, 192, 1097-1100.	2.5	28
21	Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients. <i>Frontiers in Physiology</i> , 2020, 11, 608788.	2.8	24
22	Elevated soluble endothelial cell protein C receptor (sEPCR) levels in women with preeclampsia: A marker of endothelial activation/damage?. <i>Thrombosis Research</i> , 2012, 129, 152-157.	1.7	22
23	Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood. <i>European Journal of Anaesthesiology</i> , 2019, 36, 449-456.	1.7	22
24	Fatal case of chikungunya and concomitant thrombotic thrombocytopenic purpura in French Guiana during air flight medical evacuation. <i>Journal of Travel Medicine</i> , 2017, 24, .	3.0	19
25	D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients. <i>Viruses</i> , 2021, 13, 758.	3.3	19
26	Evaluation of a commercial assay for ADAMTS13 activity measurement. <i>Thrombosis and Haemostasis</i> , 2013, 110, 852-853.	3.4	18
27	Search for an Association between V249I and T280M CX3CR1 Genetic Polymorphisms, Endothelial Injury and Preeclampsia: The ECLAXIR Study. <i>PLoS ONE</i> , 2009, 4, e6192.	2.5	15
28	Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations?. <i>Chest</i> , 2018, 153, 288-290.	0.8	15
29	A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease. <i>British Journal of Haematology</i> , 2003, 120, 643-651.	2.5	14
30	Platelet Functions are Decreased in Obesity and Restored after Weight Loss: Evidence for a Role of the SERCA3-Dependent ADP Secretion Pathway. <i>Thrombosis and Haemostasis</i> , 2019, 119, 384-396.	3.4	13
31	Placental Overexpression of Soluble CORIN in Preeclampsia. <i>American Journal of Pathology</i> , 2020, 190, 970-976.	3.8	13
32	Plasma Serotonin is Elevated in Adult Patients with Sudden Sensorineural Hearing Loss. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1291-1299.	3.4	12
33	White blood count, D-dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID-19 patients: The French multicenter CLOTVID retrospective study. <i>European Journal of Haematology</i> , 2021, 107, 190-201.	2.2	12
34	Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis. <i>PLoS ONE</i> , 2021, 16, e0251216.	2.5	12
35	Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 81-93.	2.3	12
36	Contrast between Prevalence of HIT Antibodies and Confirmed HIT in Hospitalized COVID-19 Patients: A Prospective Study with Clinical Implications. <i>Thrombosis and Haemostasis</i> , 2021, 121, 971-975.	3.4	12

#	ARTICLE	IF	CITATIONS
37	Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease. <i>Thrombosis and Haemostasis</i> , 2006, 95, 776-781.	3.4	10
38	Influence of ethnicity on the clinical and biologic expression of pre-eclampsia in the ECLAXIR study. <i>International Journal of Gynecology and Obstetrics</i> , 2011, 115, 153-156.	2.3	7
39	Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura. <i>Thrombosis Research</i> , 2019, 181, 29-35.	1.7	7
40	No VTE Recurrence After 1-Year Follow-Up of Hospitalized Patients With COVID-19 and a VTE Event. <i>Chest</i> , 2022, 162, 226-229.	0.8	6
41	Multicentre evaluation of <sup>125</sup> I-CK Prestige for assaying plasma levels of factor IX fused with albumin (Idelvion <sup>®</sup> ). <i>Haemophilia</i> , 2019, 25, e327-e330.	2.1	5
42	HLA-DRB1*11 is a strong risk factor for acquired thrombotic thrombocytopenic purpura in children. <i>Haematologica</i> , 2020, 105, e531.	3.5	5
43	Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT). <i>European Journal of Haematology</i> , 2020, 105, 103-115.	2.2	5
44	Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases. <i>American Journal of Hematology</i> , 2021, 96, E26-E29.	4.1	5
45	Case series of massive direct oral anticoagulant ingestion: Treatment and pharmacokinetics data. <i>European Journal of Clinical Investigation</i> , 2022, , e13746.	3.4	5
46	Multifactorial hypercoagulable state associated with a thrombotic phenotype in phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG): Case report and brief review of the literature. <i>Thrombosis Research</i> , 2019, 178, 75-78.	1.7	4
47	The clinical picture of thrombotic microangiopathy in patients older than 60 years of age. <i>British Journal of Haematology</i> , 2021, 192, e25-e28.	2.5	3
48	Performance of Diagnostic Scores in Thrombotic Microangiopathy Patients in the Intensive Care Unit: A Monocentric Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1427-1434.	3.4	2
49	Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 612-623.	1.6	0